News

Champions Oncology, Addario Lung Cancer Medical Institute partner

Friday, August 18, 2017

Champions Oncology, a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announced a collaboration with The Addario Lung Cancer Medical Institute (ALCMI) to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement. These models will further expand Champions’ TumorGraft bank offerings in non-small cell lung cancer for translational oncology research for academic and industry customers. Champions’ global infrastructure will be leveraged to support this multi-year program.

[Read More]

LifeNet Health to create 321 new jobs in Virginia

Friday, August 18, 2017

LifeNet Health, a global regenerative medicine company, has announced that it will invest $12.25 million to expand its global headquarters operation in the City of Virginia Beach. The non-profit will add a 100,000-square-foot warehouse, 20,000 square feet of office space, and an 18,000-square-foot R&D and production facility across three campuses. Virginia successfully competed against Florida, North Carolina, and Washington for the project, which will create 321 new jobs.

[Read More]

Context Therapeutics initiates three research collaborations

Thursday, August 17, 2017

Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis and neurodegenerative disease, has entered into agreements with three research partners. The company will collaborate with experts in the field of Sigma1 protein and its role in disease biology at the Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer. Context will work with investigators at these institutions to determine the role of Sigma1 in certain animal disease models and to evaluate the activity of its proprietary Sigma1 inhibitors in biopsy explant models, animal models, and human cellular systems.

[Read More]

Cancer Genetics acquires vivoPharm

Thursday, August 17, 2017

Cancer Genetics and vivoPharm have entered into a definitive agreement for Cancer Genetics to acquire vivoPharm for approximately $12 million. This transaction will significantly strengthen CGI’s position in oncology discovery, in vivo and in vitrodrug development and early phase clinical trial testing for biotechnology and pharmaceutical companies. With over a decade of experience in delivering a wide range of discovery and preclinical services to support drug development, target validation and biomarker analysis, vivoPharm has supported over 200 IND submissions for innovative therapies, with a significant focus on immuno-oncology.

[Read More]

Walgreens launches Center for Health & Wellbeing Research

Thursday, August 17, 2017

Walgreens announced the launch of its Center for Health & Wellbeing Research, a website that features more than 50 Walgreens outcomes studies completed over the past six years. Areas of research include access to care and patient experience, adherence and clinical outcomes, digital health and member engagement, health care costs, HIV and specialty pharmacy, vaccinations and more.

[Read More]

Takeda, Stanford University announce alliance

Thursday, August 17, 2017

Takeda Pharmaceutical has announced a collaboration with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM), which will help transform novel Stanford research into next-generation treatments for diseases. Through this unique collaboration, Takeda and Stanford will identify projects on the path to therapeutic discoveries and accelerate the process of bringing these drugs to market to serve patients with unmet needs.

[Read More]